Biocon Limited EBIT

Biocon Limited (BIOCON.NS) currently reports a EBIT of $14B as of June 2026. That compares with $16B in the prior-year period — down 14.3% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Biocon Limited's EBIT history and peer comparisons.

Biocon Limited's EBIT decreased from $16B to $14B — a 14.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biocon Limited's EBIT of $14B is lower than the Healthcare sector average of $110B. That is roughly 87.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Biocon Limited reported $14B in EBIT as of June 2026. That compares with $16B in the prior-year period — down 14.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $14B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Biocon Limited, and consider following BIOCON.NS for alerts when major investors trade the stock.